患者报告结局作为慢性肝病研究中新兴的生物标志物。 - Suppr | 超能文献

Patient reported outcomes as emerging biomarkers in chronic liver disease research.

作者信息

Verma Manisha

机构信息

Einstein Healthcare Network, Department of Digestive Diseases and Transplantation, Philadelphia.

出版信息

J Hepatol. 2020 Jun;72(6):1215-1216. doi: 10.1016/j.jhep.2020.02.010. Epub 2020 Mar 17.

DOI:10.1016/j.jhep.2020.02.010

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Patient reported outcomes as emerging biomarkers in chronic liver disease research.患者报告结局作为慢性肝病研究中新兴的生物标志物。

J Hepatol. 2020 Jun;72(6):1215-1216. doi: 10.1016/j.jhep.2020.02.010. Epub 2020 Mar 17.

2

Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.直接抗病毒药物成功清除丙型肝炎病毒后肝脏硬度降低的背后原因。

Turk J Gastroenterol. 2022 Feb;33(2):169-170. doi: 10.5152/tjg.2021.20736.

3

Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?对直接作用抗病毒药物的持续病毒学应答是否是丙型肝炎临床结局的有效替代终点？

Clin Infect Dis. 2021 Mar 1;72(5):787-788. doi: 10.1093/cid/ciaa147.

4

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.M2BPGi 用于评估丙型肝炎直接作用抗病毒药物治疗患者的肝纤维化。

World J Gastroenterol. 2020 Jun 7;26(21):2864-2876. doi: 10.3748/wjg.v26.i21.2864.

5

Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.丙型肝炎病毒6型感染的经治患者的持续病毒学应答：1例报告病例的随访

Am J Health Syst Pharm. 2017 Apr 15;74(8):555. doi: 10.2146/ajhp170018.

6

α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.干扰素治疗后甲胎蛋白水平可预测病毒学持续应答患者肝纤维化的消退情况。

J Gastroenterol Hepatol. 2016 May;31(5):1001-8. doi: 10.1111/jgh.13245.

7

Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens.在使用不含利巴韦林的直接抗病毒方案治疗丙型肝炎期间实验室监测的效用

J Viral Hepat. 2019 Jun;26(6):778-781. doi: 10.1111/jvh.13083. Epub 2019 Mar 25.

8

Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.持续病毒学应答对丙型肝炎相关肝硬化短期临床结局的影响

Eur J Gastroenterol Hepatol. 2018 Mar;30(3):296-301. doi: 10.1097/MEG.0000000000001032.

9

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.基线血清低密度脂蛋白胆固醇水平可预测HIV/丙型肝炎病毒合并感染患者对丙型肝炎病毒治疗的反应。

AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3.

10

Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?丙型肝炎：成功治疗是否改变其自然史和生活质量？

Gastroenterol Clin North Am. 2020 Jun;49(2):301-314. doi: 10.1016/j.gtc.2020.01.007. Epub 2020 Mar 29.

引用本文的文献

1

A conceptual model for chronic hepatitis B and content validity of the Hepatitis B Quality of Life (HBQOL) instrument.慢性乙型肝炎的概念模型及乙肝生活质量（HBQOL）量表的内容效度

J Patient Rep Outcomes. 2024 Mar 4;8(1):29. doi: 10.1186/s41687-023-00675-8.